TARO — Taro Pharmaceutical Industries Income Statement
0.000.00%
Last trade - 00:00
- $1.59bn
- $685.84m
- $572.95m
- 98
- 54
- 91
- 94
2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 670 | 645 | 549 | 561 | 573 |
Cost of Revenue | |||||
Gross Profit | 446 | 400 | 297 | 293 | 268 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 374 | 398 | 963 | 498 | 555 |
Operating Profit | 296 | 247 | -414 | 63.5 | 17.7 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 357 | 298 | -391 | 77.9 | 38.2 |
Provision for Income Taxes | |||||
Net Income After Taxes | 282 | 245 | -401 | 58.3 | 25.4 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | 282 | 244 | -387 | 58.3 | 25.4 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 282 | 244 | -387 | 58.3 | 25.4 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 7.15 | 6.35 | -0.611 | 2.77 | 0.677 |
Special Dividends per Share |